Kala-azar Elimination Programme
On this page
Direct answer
Kala-azar elimination is defined arithmetically: fewer than one case per 10,000 population per year at block primary health centre level, sustained — and India's programme, with a 2005 inter-country agreement with Bangladesh and Nepal, has driven cases from tens of thousands in the early 1990s to below a thousand annually in recent years. The strategy rests on four pillars: active and passive case detection with the rK39 rapid test for fever of two weeks or more with splenomegaly; single-dose liposomal amphotericin B (10 mg/kg infusion) as first-line treatment, supplied free through a WHO-mediated arrangement; indoor residual spraying with synthetic pyrethroids after DDT was withdrawn in the mid-2010s; and post-kala-azar dermal leishmaniasis (PKDL) search, since PKDL cases keep the parasite circulating. Bihar carries the bulk of the burden, with Jharkhand, West Bengal and Uttar Pradesh completing the endemic map; the vector is the sandfly Phlebotomus argentipes.
What you must remember
- The threshold: elimination means under 1 case per 10,000 per year at block (sub-district) level — not state or national averaging, a deliberate viva trap.
- Diagnosis: fever of 2 weeks or more with splenomegaly in an endemic area; rK39 immunochromatographic strip as the programme's rapid test; spleen or bone-marrow aspiration for confirmation where needed.
- Treatment to quote: single-dose liposomal amphotericin B 10 mg/kg intravenous infusion as first-line (adopted in national guidelines in the 2010s); alternatives include oral miltefosine (28 days) and paromomycin; untreated visceral leishmaniasis is nearly always fatal.
- PKDL: post-kala-azar dermal leishmaniasis appears after treatment of visceral disease — hypopigmented patches, nodules — treated with miltefosine for weeks; PKDL patients are the recognised reservoir sustaining transmission.
- Vector control: indoor residual spraying with synthetic pyrethroids (DDT discontinued from the mid-2010s), targeting walls and cattle sheds where Phlebotomus argentipes rests; sandflies are weak fliers, so bednets and plastered walls matter.
- Geography: four endemic states — Bihar (the large majority), Jharkhand, West Bengal, Uttar Pradesh; village-level micro-stratification directs spraying.
- Trajectory: targets set for 2010 were revised repeatedly (2015, 2017, 2020, 2023); India has met the block-level threshold recently and is moving toward WHO validation (per current programme reports).
From outbreak numbers to elimination arithmetic — one village's story
A villager in Bihar has two weeks of fever, weight loss and a dragging left upper abdomen; the ASHA flags him, the ANM performs an rK39 test, and the positive strip plus splenomegaly makes him a programme case. He receives single-day liposomal amphotericin B under observation — a transformation worth understanding: the older sodium antimony gluconate needed a month of painful injections amid rising resistance, and oral miltefosine demanded weeks of adherence; one infusion converted kala-azar from a hospital-month to an outpatient-day disease. His and neighbours' houses are line-listed for spraying; contacts are examined; and he is followed twelve months to catch PKDL, which can seed the next transmission cycle.
The recent history is the classic elimination endgame: as cases fell below threshold, the problem shifted from treating crowds to finding the last few — active case search, incentivised voluntary reporting, PKDL camps — then validation paperwork, since WHO elimination status is certified, not self-declared. This endgame pattern (detect-treat-track-certify) is identical to polio, yaws and malaria frameworks and is the transferable lesson examiners reward.
Where students slip
Three slips recur. First, the threshold's denominator: candidates say "less than 1 per 10,000 population" without specifying block level, losing the point that averaging at state level hides endemic villages. Second, treatment drift: quoting antimonials as first-line dates the answer — single-dose liposomal amphotericin B at 10 mg/kg is the current national first line, with miltefosine as the oral alternative and the mainstay for PKDL. Third, vector confusion: the sandfly — silent, weak-flying, indoor-resting — transmits leishmania, which is why indoor residual spraying and bednets, not larval control, are the tools. A sharp differentiator for theory answers: kala-azar is often called the second-largest parasitic killer after malaria, and linking elimination to the 2005 India-Bangladesh-Nepal memorandum shows you know this is a regional, synchronised programme — the parasite does not respect the border.
Frequently asked questions
What is the elimination threshold for kala-azar?
Fewer than one case per 10,000 population per year at block primary health centre level, sustained over time — the block, not the state, is the unit of assessment.
What is first-line treatment under the programme?
A single infusion of liposomal amphotericin B at 10 mg/kg, replacing older antimonial regimens; miltefosine orally and paromomycin are alternatives, and miltefosine is the standard for PKDL.
Which test does the programme use for field diagnosis?
The rK39 immunochromatographic rapid test on a patient with fever of two weeks or more and splenomegaly in an endemic district, with parasitological confirmation reserved for doubtful cases.
Why does PKDL matter for elimination?
Post-kala-azar dermal leishmaniasis patients harbour parasites in skin lesions long after cure of visceral disease, acting as the residual human reservoir that can reignite transmission.
Which states and vector define Indian kala-azar?
Bihar, Jharkhand, West Bengal and Uttar Pradesh are the endemic states, and Phlebotomus argentipes sandflies — indoor-resting, weak fliers — transmit Leishmania donovani.